05 November 2014
Vol 6, Issue 261

About The Cover

Cover image expansion

ONLINE COVER Crossing the Rubicon. In order for therapeutic antibodies to be useful for treating neurological diseases, they must be able to cross the mammalian blood-brain barrier (red), which separates the circulation from brain tissue (brown). By designing humanized bispecific antibodies (blue) with one arm of the antibody directed against the transferrin receptor and the other arm directed against the therapeutic target (in this case, the enzyme BACE1), Yu et al now show that these bispecific antibodies are able to cross the blood-brain barrier of nonhuman primates. They demonstrate that their bispecific antibodies enter the primate brain and target the BACE1 enzyme leading to a reduction in amyloid-β, a peptide implicated in Alzheimer's disease. [CREDIT: V. ALTOUNIAN/SCIENCE TRANSLATIONAL MEDICINE]